Table 2 Open immunotherapy trials in glioblastomas.
From: New approaches to targeted drug therapy of intracranial tumors
Trial name | Target | Phase | Indication | Drug | Trial number |
|---|---|---|---|---|---|
Anti-PD-1/PD-L1 | |||||
 Neo-adjuvant Nivolumab in Glioblastoma (Neo-nivo) | Anti-PD-1 | II | Primary/Recurrent GBM | Nivolumab | NCT02567843 |
 Pharmacodynamics of Pembrolizumab in Recurrent Glioblastoma | Anti-PD-1 | II | Recurrent GBM | Pembrolizumab | NCT02387645 |
Anti-CTLA4 | |||||
 Tremelimumab + Durvalumab in Malignant Glioma | Anti-CTLA4 and Anti-PD-1 | II | Recurrent GBM | Tremelimumab, Durvalumab | NCT02798743 |
Tumor-Focused Therapies | |||||
 Pembrolizumab + Laser Ablation in Malignant Gliomas | Anti-PD-1 | I/II | Recurrent GBM | Pembrolizumab | NCT02367890 |
Immune Therapy Combinations | |||||
 Anti-LAG-3 with Urelumab and Nivolumab | Anti-LAG3 and CD137 Agonist | I | Recurrent GBM | Nivolumab, Urelumab | NCT02643210 |
Targeted Therapy Combinations | |||||
 Nivolumab + Bevacizumab | Anti-PD-1 and Anti-VEGF | II | Recurrent GBM | Nivolumab, Bevacizumab | NCT03456590 |
 Combination of Adenovirus + Pembrolizumab | Anti-PD-1 and Oncolytic Virus | II | Recurrent GBM | Pembrolizumab | NCT02799788 |
